Base de dados : MEDLINE
Pesquisa : D27.505.954.427.700 [Categoria DeCS]
Referências encontradas : 18366 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1837 ir para página                         

  1 / 18366 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28749090
[Au] Autor:Yoon HS; Hattori K; Ogawa S; Sasayama D; Ota M; Teraishi T; Kunugi H
[Ad] Endereço:Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
[Ti] Título:Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder.
[So] Source:J Clin Psychiatry;78(8):e947-e956, 2017 Sep/Oct.
[Is] ISSN:1555-2101
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Many studies have investigated cerebrospinal fluid (CSF) monoamine metabolite levels in depressive disorders. However, their clinical significance is still unclear. We tried to determine whether CSF monoamine metabolite levels could be a state-dependent marker for major depressive disorder (MDD) based on analyses stratified by clinical variables in a relatively large sample. METHODS: Subjects were 75 patients with MDD according to DSM-IV criteria and 87 healthy controls, matched for age, sex, and ethnicity (Japanese). They were recruited between May 2010 and November 2013. We measured homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) in CSF samples by high-performance liquid chromatography. We analyzed the relationships of the metabolite levels with age, sex, diagnosis, psychotropic medication use, and depression severity. RESULTS: There was a weak positive correlation between age and 5-HIAA levels in controls (ρ = 0.26, P < .016) and a similar trend in patients, while sex was unrelated to any metabolite. All monoamine metabolites in moderately to severely depressed patients (17-item Hamilton Depression Rating Scale score > 12) were significantly lower than those in controls (P < .0005 for all 3 metabolites). We found that antidepressants decreased the levels of 5-HIAA (ρ = -0.39, P < .001) and MHPG (ρ = -0.49, P < .0001) and that antipsychotics increased levels of HVA (ρ = 0.24, P < .05). There was a strong correlation between HVA and 5-HIAA levels (controls: ρ = 0.79, P = .000001; MDD: ρ = 0.66, P = .000001). HVA levels (ρ = -0.43, P < .001) and 5-HIAA levels (ρ = -0.23, P < .05), but not MHPG levels (ρ = -0.18, P > .1), were related to depression severity. CONCLUSIONS: CSF 5-HIAA and HVA levels could be state-dependent markers in MDD patients. Since 5-HIAA levels greatly decrease with the use of antidepressants, HVA levels might be more useful in the clinical setting.
[Mh] Termos MeSH primário: Transtorno Depressivo Maior
Ácido Homovanílico/líquido cefalorraquidiano
Indóis/líquido cefalorraquidiano
Metoxi-Hidroxifenilglicol/líquido cefalorraquidiano
Psicotrópicos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Biomarcadores/líquido cefalorraquidiano
Líquido Cefalorraquidiano/efeitos dos fármacos
Líquido Cefalorraquidiano/metabolismo
Cromatografia Líquida/métodos
Transtorno Depressivo Maior/líquido cefalorraquidiano
Transtorno Depressivo Maior/diagnóstico
Transtorno Depressivo Maior/tratamento farmacológico
Transtorno Depressivo Maior/psicologia
Manual Diagnóstico e Estatístico de Transtornos Mentais
Feminino
Seres Humanos
Japão
Masculino
Meia-Idade
Escalas de Graduação Psiquiátrica
Estatística como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Indoles); 0 (Psychotropic Drugs); 534-82-7 (Methoxyhydroxyphenylglycol); 5SW11R7M7M (indole-3-lactic acid); X77S6GMS36 (Homovanillic Acid)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE


  2 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29335539
[Au] Autor:Eimon PM; Ghannad-Rezaie M; De Rienzo G; Allalou A; Wu Y; Gao M; Roy A; Skolnick J; Yanik MF
[Ad] Endereço:Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA. peter.eimon@gmail.com.
[Ti] Título:Brain activity patterns in high-throughput electrophysiology screen predict both drug efficacies and side effects.
[So] Source:Nat Commun;9(1):219, 2018 01 15.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Neurological drugs are often associated with serious side effects, yet drug screens typically focus only on efficacy. We demonstrate a novel paradigm utilizing high-throughput in vivo electrophysiology and brain activity patterns (BAPs). A platform with high sensitivity records local field potentials (LFPs) simultaneously from many zebrafish larvae over extended periods. We show that BAPs from larvae experiencing epileptic seizures or drug-induced side effects have substantially reduced complexity (entropy), similar to reduced LFP complexity observed in Parkinson's disease. To determine whether drugs that enhance BAP complexity produces positive outcomes, we used light pulses to trigger seizures in a model of Dravet syndrome, an intractable genetic epilepsy. The highest-ranked compounds identified by BAP analysis exhibit far greater anti-seizure efficacy and fewer side effects during subsequent in-depth behavioral assessment. This high correlation with behavioral outcomes illustrates the power of brain activity pattern-based screens and identifies novel therapeutic candidates with minimal side effects.
[Mh] Termos MeSH primário: Encéfalo/fisiopatologia
Fenômenos Eletrofisiológicos
Psicotrópicos/farmacologia
Peixe-Zebra/fisiologia
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Eletrofisiologia/métodos
Epilepsias Mioclônicas/diagnóstico
Epilepsias Mioclônicas/fisiopatologia
Seres Humanos
Larva/efeitos dos fármacos
Larva/genética
Larva/fisiologia
Psicotrópicos/toxicidade
Peixe-Zebra/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Psychotropic Drugs)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02404-4


  3 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Roesler, Rafael
Texto completo
[PMID]:28452904
[Au] Autor:Marchezan J; Becker M; Schwartsmann G; Ohlweiler L; Roesler R; Renck LB; Gonçalves MMM; Ranzan J; Riesgo RDS
[Ad] Endereço:*Postgraduate Program in Child and Adolescent Health, School of Medicine, Federal University of Rio Grande do Sul; †Department of Pediatrics, Child Neurology Unit, Hospital de Clínicas de Porto Alegre; ‡Department of Internal Medicine, School of Medicine, Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), §Department of Pharmacology, Institute for Basic Health Sciences, Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), and ∥Department of Pediatrics, Child Neurology Unit, Postgraduate Program in Child and Adolescent Health, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
[Ti] Título:A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism.
[So] Source:Clin Neuropharmacol;40(3):108-112, 2017 May/Jun.
[Is] ISSN:1537-162X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to evaluate the efficacy, safety, and tolerability of gastrin-releasing peptide (GRP) compared with placebo in autism spectrum disorder symptoms. METHODOLOGY: This is a randomized, double-blind, placebo-controlled crossover trial using GRP 160 pmol/kg for 4 consecutive days in 10 children with autism. Outcomes were measured by the Aberrant Behavior Checklist (ABC) scale. RESULTS: All participants were boys, aged between 4 and 9 years. There was a reduction in the scores of the ABC range and its subscales after use GRP and placebo. The reduction was more prominent with GRP, particularly in the subscale "hyperactivity and noncompliance," but there was no statistical difference between the results (P = 0.334). After a week of infusion, 5 children showed improvement of 25% or greater in the total score of the ABC scale with GRP use and 2 with placebo use; however, there was no statistical difference (P = 0.375). There were no adverse effects, changes in vital signs, or laboratory abnormalities associated with the use of GRP. CONCLUSIONS: The results of this study, despite the small sample size, reinforce previous data on the safety of the GRP in short-term use. There is a need for further research with other designs and a larger sample size to evaluate the efficacy and safety of GRP in children with autism.
[Mh] Termos MeSH primário: Transtorno do Espectro Autista/tratamento farmacológico
Comportamento Infantil/efeitos dos fármacos
Peptídeo Liberador de Gastrina/uso terapêutico
Psicotrópicos/uso terapêutico
[Mh] Termos MeSH secundário: Antiulcerosos/uso terapêutico
Anticonvulsivantes/efeitos adversos
Anticonvulsivantes/uso terapêutico
Antipsicóticos/efeitos adversos
Antipsicóticos/uso terapêutico
Transtorno do Espectro Autista/fisiopatologia
Transtorno do Espectro Autista/psicologia
Criança
Pré-Escolar
Terapia Combinada/efeitos adversos
Estudos Cross-Over
Manual Diagnóstico e Estatístico de Transtornos Mentais
Método Duplo-Cego
Quimioterapia Combinada/efeitos adversos
Seguimentos
Peptídeo Liberador de Gastrina/administração & dosagem
Peptídeo Liberador de Gastrina/efeitos adversos
Seres Humanos
Infusões Intravenosas
Masculino
Omeprazol/uso terapêutico
Escalas de Graduação Psiquiátrica
Psicotrópicos/administração & dosagem
Psicotrópicos/efeitos adversos
Reprodutibilidade dos Testes
Índice de Gravidade de Doença
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Anticonvulsants); 0 (Antipsychotic Agents); 0 (Psychotropic Drugs); 80043-53-4 (Gastrin-Releasing Peptide); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1097/WNF.0000000000000213


  4 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29368473
[Au] Autor:Sharma ER; Shuler FD; Loudin S
[Ti] Título:Legal Aspects of Neonatal Abstinence Syndrome.
[So] Source:W V Med J;112(5):19, 2016 Sep-Oct.
[Is] ISSN:0043-3284
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Tempo de Internação/legislação & jurisprudência
Síndrome de Abstinência Neonatal
Admissão do Paciente/legislação & jurisprudência
Complicações na Gravidez
[Mh] Termos MeSH secundário: Feminino
Idade Gestacional
Seres Humanos
Recém-Nascido
Unidades de Terapia Intensiva Neonatal
Tempo de Internação/estatística & dados numéricos
Síndrome de Abstinência Neonatal/epidemiologia
Síndrome de Abstinência Neonatal/etiologia
Admissão do Paciente/estatística & dados numéricos
Gravidez
Complicações na Gravidez/epidemiologia
Complicações na Gravidez/etiologia
Prevalência
Psicotrópicos/efeitos adversos
Drogas Ilícitas/efeitos adversos
Drogas Ilícitas/legislação & jurisprudência
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
Transtornos Relacionados ao Uso de Substâncias/etiologia
West Virginia/epidemiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; EDITORIAL
[Nm] Nome de substância:
0 (Psychotropic Drugs); 0 (Street Drugs)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  5 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28746793
[Au] Autor:de Morais DR; Barbosa IL; Cunha KF; Tripodi GL; Angolini CFF; Franco MF; de Aquino EM; Eberlin MN; Costa JL
[Ad] Endereço:ThoMSon Mass Spectrometry Laboratory, University of Campinas, Institute of Chemistry, Campinas, São Paulo, 13083-970, Brazil.
[Ti] Título:EASI-IMS an expedite and secure technique to screen for 25I-NBOH in blotter papers.
[So] Source:J Mass Spectrom;52(10):701-706, 2017 Oct.
[Is] ISSN:1096-9888
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The increasing number of new psychoactive substances (NPS) and their quick worldwide spreading, often only slightly modified in the form of new derivatives and analogues, have brought the need for fast, wide-ranging, and unequivocal identification methods in clinical and forensic investigations. Because it usually provides secure results, gas chromatography coupled to mass spectrometry (GC-MS) has been routinely employed as the standard technique for the detection of NPS in blotter papers. For 25I-NBOH (N-(2-hydroxybenzyl)-2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-aminium), however, GC-MS analysis of an blotter paper extract leads to incorrect results. In this work, we investigated whether easy ambient sonic-spray mass spectrometry imaging (EASI-IMS), and ambient ionization MS method can be applied directly to the surface of the sample requiring therefore no extraction or sample preparations, would serve as an efficient, sensitive, and secure alternative for 25I-NBOH screening.
[Mh] Termos MeSH primário: Cromatografia Gasosa-Espectrometria de Massas/métodos
Psicotrópicos/análise
Compostos de Amônio Quaternário/análise
Compostos de Amônio Quaternário/química
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão/métodos
Seres Humanos
Papel
Psicotrópicos/química
Sensibilidade e Especificidade
Espectrometria de Massas por Ionização por Electrospray/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (N-(2-hydroxybenzyl)-2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-aminium); 0 (Psychotropic Drugs); 0 (Quaternary Ammonium Compounds)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1002/jms.3977


  6 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29217505
[Au] Autor:Bould H; Newbegin C; Stewart A; Stein A; Fazel M
[Ad] Endereço:Department of Psychiatry, Warneford Hospital, Oxford, UK helen.bould@psych.ox.ac.uk.
[Ti] Título:Eating disorders in children and young people.
[So] Source:BMJ;359:j5245, 2017 12 07.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Transtornos da Alimentação e da Ingestão de Alimentos/diagnóstico
Transtornos da Alimentação e da Ingestão de Alimentos/terapia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Comorbidade
Diagnóstico Diferencial
Suplementos Nutricionais
Gerenciamento Clínico
Transtornos da Alimentação e da Ingestão de Alimentos/complicações
Transtornos da Alimentação e da Ingestão de Alimentos/psicologia
Feminino
Seres Humanos
Masculino
Minerais/uso terapêutico
Psicoterapia/métodos
Psicotrópicos/uso terapêutico
Medição de Risco/métodos
Vitaminas/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Minerals); 0 (Psychotropic Drugs); 0 (Vitamins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5245


  7 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28463346
[Au] Autor:Joober R; Cole K; Tabbane K; Boivin DB
[Ad] Endereço:McGill University, Douglas Mental Health University Institute, Frank B. Common Pavilion, Montréal, QC, Canada. E-mail: ridha.joober@douglas.mcgill.ca.
[Ti] Título:An algorithmic approach to the management of insomnia in patients with schizophrenia.
[So] Source:Ann Clin Psychiatry;29(2):133-144, 2017 May.
[Is] ISSN:1547-3325
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Insomnia is an important problem in patients with schizophrenia and is an emerging area of interest for researchers. We propose a treatment algorithm that synthesizes the various psychological and pharmacological interventions for insomnia in this population. METHODS: Our selective literature review incorporates English language articles from 4 medicine databases through May 2016. Selected articles discuss risk factors and treatments for insomnia, as well as comorbid sleep disorders that coexist in this population. RESULTS: Various lifestyle factors and comorbid sleep disorders may predispose patients with schizophrenia to insomnia. Cognitive-behavioral therapy for insomnia shows promising results in treating insomnia in patients with schizophrenia spectrum disorders. Additionally, studies of eszopiclone and melatonin have yielded significant results in short-term trials that evaluated both subjective and objective insomnia symptoms. CONCLUSIONS: We have summarized the relevant literature regarding the treatment of insomnia in this patient population and propose an algorithm comprising 6 sequential steps, beginning with the assessment of sleep complaints and medication adherence. This is followed by a targeted treatment of any co-occurring sleep disorders, and ends with psychoeducation, cognitive-behavioral therapy, and pharmacotherapy. This algorithm provides a detailed guideline to improve the assessment and therapeutic intervention for managing insomnia among patients with schizophrenia.
[Mh] Termos MeSH primário: Terapia Cognitiva/métodos
Psicotrópicos/farmacologia
Esquizofrenia/complicações
Distúrbios do Início e da Manutenção do Sono
[Mh] Termos MeSH secundário: Algoritmos
Gerenciamento Clínico
Seres Humanos
Distúrbios do Início e da Manutenção do Sono/etiologia
Distúrbios do Início e da Manutenção do Sono/psicologia
Distúrbios do Início e da Manutenção do Sono/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Psychotropic Drugs)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  8 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28463343
[Au] Autor:Correll CU; Yu X; Xiang Y; Kane JM; Masand P
[Ti] Título:Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting.
[So] Source:Ann Clin Psychiatry;29(2):92-107, 2017 05.
[Is] ISSN:1547-3325
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Schizophrenia and bipolar disorders are chronic illnesses that commonly present with symptoms of acute agitation and aggression. These symptoms must be managed rapidly to prevent potential harm to the patient and others, including their caregivers, peers, and health care workers. A number of treatment options are available to clinicians to manage acute agitation and aggression, including non-pharmacologic behavioral and environmental de-escalation strategies, as well as biological treatment options such as pharmacologic agents and electroconvulsive therapy. We summarize the available biological treatment options for patients with schizophrenia or bipolar disorder presenting with acute agitation or aggression in the inpatient setting, focusing on antipsychotics. METHODS: The following searches were used in PubMed to obtain the most relevant advances in treating schizophrenia or bipolar disorder with acute agitation and aggression: (agitation, agitated, aggression, aggressive, hostile, hostility, violent, or violence) and (schizophr*, psychosis, psychot*, psychos*, mania, manic, or bipolar) and (*pharmacologic, antipsychotic*, neuroleptic*, antiepileptic*, anti-seizure*, mood stabilizer*, lithium, benzodiazepine*, beta blocker, beta-blocker, alpha2, alpha-2, *histamine*, electroconvulsive, ECT, shock, or transcranial). Individual searches were performed for each drug class. The studies were limited to peer-reviewed, English-language, and human studies. Most were placebo-controlled randomized controlled trials (RCTs) or meta-analyses. RESULTS: Among pharmacologic agents, antipsychotics, benzodiazepines, anticonvulsants, and lithium have been studied in randomized trials. Some typical and, more recently, atypical antipsychotics are available as both oral and short-acting intramuscular (IM) formulations, with 1 typical antipsychotic also available as an inhalable formulation. CONCLUSIONS: Among the pharmacologic agents studied in RCTs, atypical antipsychotics have the best evidence to support efficacy both in oral and short-acting IM formulations, as well as in one instance in an inhalable formulation.
[Mh] Termos MeSH primário: Transtorno Bipolar
Agitação Psicomotora/terapia
Psicotrópicos/farmacologia
Esquizofrenia/terapia
[Mh] Termos MeSH secundário: Agressão/efeitos dos fármacos
Agressão/psicologia
Transtorno Bipolar/psicologia
Transtorno Bipolar/terapia
Eletroconvulsoterapia/métodos
Serviços de Emergência Psiquiátrica/métodos
Seres Humanos
Agitação Psicomotora/psicologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Psicologia do Esquizofrênico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Psychotropic Drugs)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  9 / 18366 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29277574
[Au] Autor:Caspar AT; Meyer MR; Maurer HH
[Ad] Endereço:Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Homburg, Germany.
[Ti] Título:Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.
[So] Source:Toxicol Lett;285:1-8, 2018 Mar 15.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A huge number of new chemical derivatives of known drugs of abuse, so-called new psychoactive substances (NPS), are sold and consumed without prior preclinical and clinical testing. For assessing the elimination behaviors, determination of the kinetic constants K and V of the cytochrome P450 (CYP) isoforms involved in the hepatic metabolism of NPS could help to predict their contributions to hepatic clearance, drug-drug interactions and polymorphisms. Therefore, the aims of the present study were to determine the K and V values for CYP isoforms using the substrate depletion approach for the six N-2-methoxybenzyl (NBOMe)-derived NPS 25B-NBOMe, 25C-NBOMe, 25I-NBOMe, 3,4-DMA-NBOMe, 4-EA-NBOMe, and 4-MMA-NBOMe. Furthermore, the contributions of each CYP isozyme to the hepatic net clearance were elucidated using the relative activity factor approach. Several CYPs including CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A4 were identified to be involved in the metabolism of the investigated compounds. The determined K values ranged from 0.010 µM (CYP2D6, 4-MMA-NBOMe) to 13 µM (CYP2B6, 4-EA-NBOMe). All NBOMes were good substrates of CYP2C19 and CYP2D6 resulting in very low K values in the nanomolar range. The main contributors to hepatic net clearance were CYP2D6 for 25B-NBOMe (69%), 25C-NBOMe (83%), 25I-NBOMe (61%), 3,4-DMA-NBOMe (89%) as well as for 4-EA-NBOMe (62%) and CYP2C19 for 4-MMA-NBOMe (64%). As more than one isoform was involved in the particular steps, the risk of harm associated with drug-drug interactions might be considered low. However, in cases where substances with high contributions from polymorphically expressed CYP2C19 and CYP2D6 are encountered, inter-individual variations in metabolism and excretion cannot be excluded.
[Mh] Termos MeSH primário: Compostos de Benzil/farmacocinética
Sistema Enzimático do Citocromo P-450/metabolismo
Microssomos Hepáticos/enzimologia
Psicotrópicos/farmacocinética
Drogas Ilícitas/farmacocinética
[Mh] Termos MeSH secundário: Animais
Compostos de Benzil/química
Sistema Enzimático do Citocromo P-450/genética
Interações Medicamentosas
Seres Humanos
Técnicas In Vitro
Cinética
Taxa de Depuração Metabólica
Microssomos Hepáticos/metabolismo
Modelos Biológicos
Psicotrópicos/química
Drogas Ilícitas/química
Especificidade por Substrato
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzyl Compounds); 0 (Psychotropic Drugs); 0 (Street Drugs); 9035-51-2 (Cytochrome P-450 Enzyme System)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  10 / 18366 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29301420
[Au] Autor:Reus VI; Fochtmann LJ; Bukstein O; Eyler AE; Hilty DM; Horvitz-Lennon M; Mahoney J; Pasic J; Weaver M; Wills CD; McIntyre J; Kidd J; Yager J; Hong SH
[Ad] Endereço:From the APA Practice Guideline Writing Group (Victor I. Reus, M.D., Chair).
[Ti] Título:The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.
[So] Source:Am J Psychiatry;175(1):86-90, 2018 01 01.
[Is] ISSN:1535-7228
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Alcoolismo
Guias de Prática Clínica como Assunto
Psicotrópicos/farmacologia
[Mh] Termos MeSH secundário: Alcoolismo/diagnóstico
Alcoolismo/terapia
Seres Humanos
Administração dos Cuidados ao Paciente/métodos
Administração dos Cuidados ao Paciente/normas
Técnicas Psicológicas
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Psychotropic Drugs)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1176/appi.ajp.2017.1750101



página 1 de 1837 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde